Investing
Today's Market Winners And Losers (6/21/2012)
Published:
Last Updated:
While the Dow Jones Industrial Average, S&P 500 and NASDAQ are down slightly today after weak data on the U.S. labor market. Nevertheless, there are several big winners and losers as of midday. Three of four of today’s featured stocks are in healthcare, two of which are in pharmaceuticals. Here are the midday big winners and losers.
Biggest Winners
Shares of Onyx Pharmaceuticals (NASDAQ: ONXX) are up 37.82% to $62.33 based on trading volume of approximately 15 million shares. The company’s cancer drug, carfilzomb, received an 11 to 1 vote from a Food & Drug Administration advisory panel in favor of approval. The FDA is expected to make a final decision by next month.
Shares of Sun Healthcare Group (NASDAQ: SUNH) are up 36.16% to $8.36 on trading volume of nearly 17 million shares. The company announced Wednesday that it would be acquired by privately held Genesis HealthCare for $273.3 million. The merging of the nursing home operators will consist of 400 facilities throughout the U.S.
Biggest Losers
Shares of Bed Bath and Beyond (NASDAQ: BBBY) are down 14.89% to 62.70 based on trading volume of 7.9 million shares. The retailer predicted Wednesday its second-quarters earning would be between 97 cents and $1.03 a share, down from $1.08 that the street was expecting.
Shares of Celgene (NASDAQ: CELG) are down 11.41% to $59.50 based on trading volume of 12 million shares. The company withdrew an application to market its cancer drug, Revlimid, in the European Union. The company said it now plans on seeking approval in 2013 instead of 2012.
Sam Weigley
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.